CAR-T Cells Target Cancer, Sparing Healthy Tissues

In the field of cancer treatment, a scientific relay spanning twenty years is brewing a revolutionary breakthrough. In a new study, researchers from research institutions such as the University of Montreal and the National Cancer Institute have successfully created more effectiveimmunityCells that can fight cancer without damaging healthy tissue. Related research results are published inCellin the magazine.

“This story goes back nearly 20 years ago. I mainly wanted to build a mathematical model of what is happening in biology to improve our understanding of it,” said Professor Paul François, a co-corresponding author of the paper and a department of biochemistry and molecular medicine at the University of Montreal.

In 2005, Professor Paul François, a theoretical biologist at the University of Montreal, was deeply troubled by a fundamental question when attending the immunology seminar at Dr. Grégoire Altan-Bonnet of the National Cancer Institute: “How do T cells achieve complex decisions through simple receptors?” This collision of ideas has spawned two decades of interdisciplinary collaboration.

Research team integrates Altan-Bonnet lab’s high-throughput robot platform (single-day analysis >10⁴A multi-scale mathematical model of T-cell-target cell interaction event with Professor François’s team revealed for the first time the bidirectional regulation of T-cell receptors (TCRs): “TCR is not only an accelerator pedal for immune responses, but also an accurate brake system.”

Immune system judo

In recent years,CAR-TCell immunotherapy (using chimeric antigen receptors) has revolutionized the fight against cancer. Combined with other tools (chemotherapy, radiotherapy), this new therapy reprograms the patient’s T cells (the “warrior” of the immune system) to attackcancer cell. “It’s kind of like judo in the immune system,” Professor François said.

In the laboratory, T cells were modified by adding synthetic chimeric antigen receptors (CARs). This receptor prompts T cells to actively destroy cancer cells, although their mechanism of identifying tumors is not very accurate, so modified T cells often attack healthy tissues.

Professor François explained, “CAR-T cells attack ovarian tumors, but they can also destroy the patient’s healthy tissue, especially the lungs. So when they attack cancer, the overreaction triggered may kill the patient.”

How to make immune cells learn to “be gentle”

So, what is the best way to regulate the immune system’s response? The research team made full use of T cell receptors (TCR), a naturally occurring receptor in T cells, where TCR can distinguish healthy cells from cancer cells by identifying different cell surface proteins. But previous studies have shown that TCR is not very effective in fighting tumors.

Nevertheless, the research team successfully mixed the two strategies together to design CAR-T cells containing TCR. Through mathematical modeling, they found that when TCR binds weakly to healthy cell surface proteins, it activates the attack command that suppresses the CAR, and when it binds strongly to cancer cells, it enhances lethality. The “antagonistic forced braking system” (AEBS) developed based on this principle enables immune cells to accurately switch “fighting mode” and “protection mode” in the tumor microenvironment.

In the mouse model of humanized solid tumors, the new dual TCR/CAR T cells showed amazing performance: these dual TCR/CAR T cells improved by 50% in anti-cancer effects than traditional CAR T cells, and at the same time reduced toxicity to healthy tissues by 90%! “For the first time, we have demonstrated that using natural inhibitory dialogue between receptors can allow the immune system to cut tumors accurately like a surgeon,” the research team said excitedly.

This study not only answers theoretical conjectures from 20 years ago, but also transforms mathematical models into patentable treatment options. The team has initiated patent applications and planned clinical trials, which are expected to bring safe and effective treatment options to patients with solid tumors. “We use mathematical language to teach the immune system to distinguish enemies and friends. This may be the ultimate form of precision medicine,” Professor François predicted.

This study marks the entry of cancer immunotherapy into the “era era of intelligent regulation” and provides a new paradigm for solving the “precision-effectiveness” paradox of CAR-T therapy. When mathematics meets immunology, human arsenal of fighting cancer is being redefined. (Biological Valley Bioon.com）

References:

Taisuke Kondo et al, Engineering TCR-controlled fuzzy logic into CAR T cells enhances therapeutic specificityCell (2025). DOI: 10.1016/j.cell.2025.03.017.